These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12687572)

  • 21. Anti-CD20 treatment in primary Sjögren's syndrome.
    Isaksen K; Jonsson R; Omdal R
    Scand J Immunol; 2008 Dec; 68(6):554-64. PubMed ID: 19000095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
    Pollard RP; Abdulahad WH; Vissink A; Hamza N; Burgerhof JG; Meijer JM; Visser A; Huitema MG; Spijkervet FK; Kallenberg CG; Bootsma H; Kroese FG
    Ann Rheum Dis; 2013 Jan; 72(1):146-8. PubMed ID: 22851468
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab.
    Ahmadi-Simab K; Lamprecht P; Nölle B; Ai M; Gross WL
    Ann Rheum Dis; 2005 Jul; 64(7):1087-8. PubMed ID: 15958765
    [No Abstract]   [Full Text] [Related]  

  • 24. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome.
    Price EJ; Rigby SP; Clancy U; Venables PJ
    J Rheumatol; 1998 May; 25(5):896-9. PubMed ID: 9598887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment.
    Meijer JM; Pijpe J; Vissink A; Kallenberg CG; Bootsma H
    Ann Rheum Dis; 2009 Feb; 68(2):284-5. PubMed ID: 19139205
    [No Abstract]   [Full Text] [Related]  

  • 26. Salivary resistin reflects local inflammation in Sjögren's syndrome.
    Boström EA; d'Elia HF; Dahlgren U; Simark-Mattsson C; Hasséus B; Carlsten H; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 Oct; 35(10):2005-11. PubMed ID: 18709689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren's syndrome.
    Ek M; Popovic K; Harris HE; Nauclér CS; Wahren-Herlenius M
    Arthritis Rheum; 2006 Jul; 54(7):2289-94. PubMed ID: 16802368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.
    Somer BG; Tsai DE; Downs L; Weinstein B; Schuster SJ;
    Arthritis Rheum; 2003 Jun; 49(3):394-8. PubMed ID: 12794796
    [No Abstract]   [Full Text] [Related]  

  • 29. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study.
    Zandbelt MM; de Wilde P; van Damme P; Hoyng CB; van de Putte L; van den Hoogen F
    J Rheumatol; 2004 Jan; 31(1):96-101. PubMed ID: 14705226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salivary enhancement: current status and future therapies.
    Atkinson JC; Baum BJ
    J Dent Educ; 2001 Oct; 65(10):1096-101. PubMed ID: 11699983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E; Hall FC
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract]   [Full Text] [Related]  

  • 32. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
    Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sjögren's syndrome: a new approach to treatment].
    Rossier V; Bart PA; Spertini F
    Rev Med Suisse; 2012 Apr; 8(337):843-7. PubMed ID: 22594008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of patients presenting with Sjogren's syndrome.
    Venables PJ
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):791-807. PubMed ID: 16979538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dehydroepiandrosterone versus placebo for Sjögren's syndrome: comment on the article by Pillemer et al.
    van Vollenhoven R
    Arthritis Rheum; 2005 Aug; 53(4):626. PubMed ID: 16082652
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of primary Sjögren's syndrome with D-penicillamine: a pilot study.
    ter Borg EJ; Haanen HC; Haas FJ; Bistervels JH; Huisman FW; Kerckhaert JA; Kallenberg CG
    Neth J Med; 2002 Nov; 60(10):402-6. PubMed ID: 12607591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trafficking of lacrimal aquaporin-5 in Sjögren's syndrome.
    Groneberg DA; Gerber A; Fischer A
    Lancet; 2001 Jun; 357(9273):2054-5. PubMed ID: 11441861
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome.
    Rihl M; Ulbricht K; Schmidt RE; Witte T
    Rheumatology (Oxford); 2009 Jul; 48(7):796-9. PubMed ID: 19433433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot clinical trial of dehydroepiandrosterone for Sjögren's syndrome: comment on the article by Pillemer et al.
    Toivanen A
    Arthritis Rheum; 2005 Aug; 53(4):626-7. PubMed ID: 16082644
    [No Abstract]   [Full Text] [Related]  

  • 40. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome.
    Tsubota K; Hirai S; King LS; Agre P; Ishida N
    Lancet; 2001 Mar; 357(9257):688-9. PubMed ID: 11247557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.